scholarly journals Effectiveness of B Vitamins and Their Interactions with Aspirin in Improving Cognitive Functioning in Older People with Mild Cognitive Impairment: Pooled Post-Hoc Analyses of Two Randomized Trials

Author(s):  
Y. Wu ◽  
A. D. Smith ◽  
H. Refsum ◽  
Timothy Kwok

Abstract Background and Objectives A randomized placebo-controlled trial found a significant negative interaction between aspirin and B vitamins in cognitive functioning in older people with mild cognitive impairment (MCI). To validate this finding, we pooled data of this trial with that of a similar B-vitamin trial (VITACOG) to examine the effectiveness of B vitamins and their interactions with aspirin in improving global cognitive functioning and slowing brain atrophy in older people with MCI. Design Pooled post-hoc analyses of two randomized placebo-controlled trials. Participants In total, 545 older people with MCI were included in the study. Intervention Placebo or B-vitamin supplements (vitamin B12, folic acid with or without vitamin B6) for 24 months. Measurements The primary outcome was the Clinical Dementia Rating scale-global score (CDR-global). The secondary outcomes were CDR-sum of box score (CDR-SOB), memory Z-score, executive function Z-score, and whole brain atrophy rate. Results 71 (26.2%) and 83 (30.3%) subjects in the active and placebo group respectively were aspirin users. Overall, B vitamins reduced whole brain atrophy rate significantly (P = 0.003), but did not have significant effect on CDR-global, CDR-SOB, memory and executive function. Aspirin use had significant negative interaction effects on B vitamins in CDR-global and CDR-SOB (Beta = 0.993, P = 0.038, and Beta = 0.583, P = 0.009, respectively), but not in memory or executive function Z-scores. Among aspirin non-users, B-vitamin group subjects had more favourable changes in CDR-global and CDR-SOB (P = 0.019 and 0.057, respectively). B vitamins significantly slowed brain atrophy in aspirin non-users (P = 0.001), but not in aspirin users, though the interaction term was not significant (Beta = 0.192, P = 0.276). Conclusion In older people with MCI, B vitamins had significantly favourable effects on global cognitive functioning and whole brain atrophy rate in those who were not taking aspirin, but not in aspirin users.

Radiology ◽  
2008 ◽  
Vol 248 (2) ◽  
pp. 590-598 ◽  
Author(s):  
Jasper D. Sluimer ◽  
Wiesje M. van der Flier ◽  
Giorgos B. Karas ◽  
Nick C. Fox ◽  
Philip Scheltens ◽  
...  

2010 ◽  
Vol 31 (5) ◽  
pp. 758-764 ◽  
Author(s):  
Jasper D. Sluimer ◽  
Femke H. Bouwman ◽  
Hugo Vrenken ◽  
Marinus A. Blankenstein ◽  
Frederik Barkhof ◽  
...  

2008 ◽  
Vol 4 ◽  
pp. T64-T64
Author(s):  
Wiesje M. van der Flier ◽  
Jasper Sluimer ◽  
Femke Bouwman ◽  
Hugo Vrenken ◽  
Marinus A. Blankenstein ◽  
...  

Neurology ◽  
2008 ◽  
Vol 70 (Issue 19, Part 2) ◽  
pp. 1836-1841 ◽  
Author(s):  
J. D. Sluimer ◽  
H. Vrenken ◽  
M. A. Blankenstein ◽  
N. C. Fox ◽  
P. Scheltens ◽  
...  

2010 ◽  
Vol 31 (9) ◽  
pp. 1601-1605 ◽  
Author(s):  
Gabriela Spulber ◽  
Eini Niskanen ◽  
Stuart MacDonald ◽  
Oded Smilovici ◽  
Kewei Chen ◽  
...  

2008 ◽  
Vol 4 ◽  
pp. T547-T547
Author(s):  
Wiesje M. Van der Flier ◽  
Jasper Sluimer ◽  
Femke H. Bouwman ◽  
Hugo Vrenken ◽  
Marinus A. Blankenstein ◽  
...  

2010 ◽  
Vol 103 (11) ◽  
pp. 1629-1634 ◽  
Author(s):  
Timothy J. Green ◽  
C. Murray Skeaff ◽  
Jennifer A. McMahon ◽  
Bernard J. Venn ◽  
Sheila M. Williams ◽  
...  

Elevated plasma total homocysteine (tHcy) is a risk factor for vascular disease but lowering tHcy with B-vitamins, including folate, has generally not reduced vascular events in secondary prevention trials. Elevated plasmaS-adenosylhomocysteine (AdoHcy) concentration may be a more sensitive indicator of vascular disease than plasma tHcy. However, unlike tHcy, plasma AdoHcy did not correlate with folate concentration in one study indicating that folate supplementation may not lower AdoHcy. Our aim was to determine whether providing B-vitamin supplements to healthy older people with elevated tHcy (>13 μmol/l) affects plasma AdoHcy andS-adenosylmethionine (AdoMet) concentrations. Healthy older participants (n276; ≥ 65 years) were randomised to receive a daily supplement containing folate (1 mg), vitamin B12(500 μg) and vitamin B6(10 mg), or placebo, for 2 years. Of these participants, we selected the first fifty participants in each treatment group and measured plasma AdoHcy and AdoMet. Plasma tHcy was 4·4 (95 % CI 3·2, 5·6;P < 0·001) μmol/l lower at 2 years in the vitamins group compared with the placebo group. At 2 years, there were no significant differences in plasma AdoMet (+4 % (95 % CI − 2, 11);P = 0·19), AdoHcy ( − 1 % (95 % CI − 10, 8);P = 0·61) or the AdoMet:AdoHcy ratio (0·22 (95 % CI − 0·04, 0·49);P = 0·10) between the two groups. In conclusion, B-vitamin supplementation of older people lowered plasma tHcy but had no effect on plasma AdoMet or AdoHcy concentration. If elevated plasma AdoHcy is detrimental, this may explain why B-vitamins have generally failed to reduce vascular events in clinical trials.


2016 ◽  
Vol 2016 ◽  
pp. 1-7 ◽  
Author(s):  
C. Guevara ◽  
K. Bulatova ◽  
G. J. Barker ◽  
G. Gonzalez ◽  
N. Crossley ◽  
...  

In multiple system atrophy (MSA) and progressive supranuclear palsy (PSP), the absence of surrogate endpoints makes clinical trials long and expensive. We aim to determine annualized whole-brain atrophy rates (a-WBAR) in idiopathic Parkinson’s disease (IPD), MSA, and PSP. Ten healthy controls, 20 IPD, 12 PSP, and 8 MSA patients were studied using a volumetric MRI technique (SIENA). In controls, the a-WBAR was0.37%±0.28(CI 95% 0.17–0.57), while in IPD a-WBAR was0.54%±0.38(CI 95% 0.32–0.68). The IPD patients did not differ from the controls. In PSP, the a-WBAR was1.26%±0.51(CI 95%: 0.95–1.58). In MSA, a-WBAR was1.65%±1.12(CI 95%: 0.71–2.59). MSA did not differ from PSP. The a-WBAR in PSP and MSA were significantly higher than in the IPD group (p=0.004andp<0.001, resp.). In PSP, the use of a-WBAR required one-half of the patients needed for clinical scales to detect a 50% reduction in their progression. In MSA, one-quarter of the patients would be needed to detect the same effect. a-WBAR is a reasonable candidate to consider as a surrogate endpoint in short clinical trials using smaller sample sizes. The confidence intervals for a-WBAR may add a potential retrospective application for a-WBAR to improve the diagnostic accuracy of MSA and PSP versus IPD.


Sign in / Sign up

Export Citation Format

Share Document